ACADIA Pharmaceuticals
ACAD
19.65
-0.09
-0.46%
ACADIA Pharmaceuticals
US · ACAD
#2404 by market cap
Listed 1970
19.65
-0.09
-0.46%
Live - 5344 symbols - heartbeat 218s ago
· 2026-10-08 07:15
Pre-market
19.80
+0.75%
After-hours
19.70
+0.25%
- Market cap
- 3.39B
- P/E (TTM)i
- 8.81
- P/Bi
- 2.59
- EPSi
- 2.30
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on ACAD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.92, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.87% YoY
Margins
- Gross margin
- 91.69%
- Operating margin
- 9.78%
- Net margin
- 36.49%
Key ratios & quality
- Altman Z-Scorei
- 5.92
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223.81M | 339.08M | 441.76M | 484.15M | 517.24M | 726.44M | 957.80M | 1.07B |
| Gross profit | 205.48M | 319.48M | 421.21M | 465.00M | 507.07M | 684.80M | 875.96M | 982.51M |
| Selling & admin expenses | 265.76M | 325.64M | 388.66M | 396.03M | 369.09M | 406.56M | 488.43M | 548.89M |
| Research & development | 187.16M | 240.39M | 319.13M | 239.42M | 361.58M | 351.62M | 303.25M | 328.80M |
| Operating profit | -247.44M | -246.55M | -286.59M | -170.44M | -223.60M | -73.38M | 84.28M | 104.81M |
| Pretax profit | -243.94M | -234.38M | -280.97M | -167.52M | -213.44M | -51.04M | 258.08M | 138.90M |
| Tax | 1.26M | 876.00K | 611.00K | 351.00K | 2.53M | 10.25M | 31.62M | -252.10M |
| Net profit | -245.19M | -235.26M | -281.58M | -167.87M | -215.98M | -61.29M | 226.45M | 391.00M |
| Basic EPS | -2 | -2 | -2 | -1 | -1 | 0 | 1 | 2 |
| Diluted EPS | -1.94 | -1.60 | -1.79 | -1.05 | -1.34 | -0.37 | 1.36 | 2.30 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 244.32M | 264.57M | 278.63M | 283.99M | 268.06M | 307.96M |
| Gross profit | 223.93M | 243.83M | 256.99M | 257.76M | 243.27M | 279.64M |
| Selling & admin expenses | 126.37M | 133.51M | 133.40M | 155.62M | 171.02M | 160.25M |
| Research & development | 78.27M | 77.95M | 87.83M | 84.76M | 76.87M | 81.56M |
| Operating profit | 19.29M | 32.37M | 35.76M | 17.39M | -4.62M | 37.84M |
| Pretax profit | 27.78M | 40.21M | 44.60M | 26.32M | 3.98M | 46.47M |
| Tax | 8.79M | 13.55M | -27.18M | -247.25M | 344.00K | 14.97M |
| Net profit | 18.99M | 26.67M | 71.78M | 273.57M | 3.64M | 31.50M |
| Basic EPS | 0 | 0 | 0 | 2 | 0 | 0 |
| Diluted EPS | 0.11 | 0.16 | 0.42 | 1.60 | 0.02 | 0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 526.11M | 760.25M | 717.62M | 617.82M | 507.94M | 616.13M | 938.32M | 1.06B |
| Cash & ST investments | 473.52M | 697.43M | 631.96M | 520.71M | 416.82M | 438.87M | 755.99M | 819.69M |
| Inventory | 4.07M | 6.34M | 9.68M | 7.88M | 6.64M | 35.82M | 21.95M | 34.67M |
| Total assets | 540.20M | 783.18M | 782.62M | 700.12M | 587.81M | 748.96M | 1.19B | 1.56B |
| Total current liabilities | 59.57M | 74.83M | 105.97M | 96.07M | 125.63M | 254.25M | 394.87M | 277.11M |
| Short-term debt | -- | 3.43M | 5.09M | 8.30M | 9.31M | 9.41M | 9.96M | 11.63M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 61,123,000.00 | 84,048,000.00 | 155,607,000.00 | 159,228,000.00 | 187,399,000.00 | 317,201,000.00 | 454,963,000.00 | 336,805,000.00 |
| Total equity | 479.08M | 699.14M | 627.01M | 540.89M | 400.41M | 431.76M | 732.79M | 1.23B |
| Retained earnings | -1.47B | -1.70B | -1.99B | -2.15B | -2.37B | -2.43B | -2.20B | -1.81B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 870.94M | 960.55M | 1.08B | 1.06B | 1.10B | 1.22B |
| Cash & ST investments | 681.58M | 762.00M | 847.02M | 819.69M | 851.46M | 956.47M |
| Inventory | 22.95M | 26.12M | 29.10M | 34.67M | 31.57M | 32.37M |
| Total assets | 1.13B | 1.23B | 1.33B | 1.56B | 1.61B | 1.74B |
| Total current liabilities | 302.53M | 330.02M | 356.58M | 277.11M | 305.52M | 361.44M |
| Short-term debt | 11.37M | 11.69M | 11.78M | 11.63M | 11.79M | 14.31M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 367,127,000.00 | 403,173,000.00 | 413,499,000.00 | 336,805,000.00 | 357,164,000.00 | 436,291,000.00 |
| Total equity | 765.24M | 822.38M | 917.27M | 1.23B | 1.25B | 1.31B |
| Retained earnings | -2.19B | -2.16B | -2.09B | -1.81B | -1.81B | -1.78B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -167.47M | -151.13M | -136.17M | -125.66M | -114.04M | 16.70M | 157.72M | 109.84M |
| Depreciation & amortization | 3.01M | 2.77M | 2.93M | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| Free cash flow | -169.57M | -152.26M | -143.75M | -126.78M | -114.04M | 16.65M | 157.20M | 105.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 306.65M | 371.85M | 81.00M | 18.16M | 8.20M | 25.13M | 6.85M | 49.88M |
| Ending cash balance | 139.58M | 194.47M | 331.80M | 153.21M | 120.62M | 194.43M | 328.36M | 185.54M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 20.32M | 63.96M | 74.29M | -48.73M | 33.98M | 100.78M |
| Depreciation & amortization | 2.95M | 2.94M | 2.95M | 2.92M | 2.99M | 3.16M |
| Free cash flow | -78.52M | 162.50M | -24.94M | 46.10M | 28.77M | 95.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.84M | 15.96M | 9.42M | 22.67M | 4.23M | 10.49M |
| Ending cash balance | 226.47M | 263.11M | 267.47M | 185.54M | 290.06M | 392.83M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -60.22 | -39.93 | -42.47 | -28.75 | -45.89 | -14.73 | 38.89 | 39.89 |
| ROA %i | -53.03 | -35.55 | -35.97 | -22.64 | -33.54 | -9.17 | 23.39 | 28.42 |
| ROIC %i | -61.18 | -40.64 | -41.34 | -26.26 | -41.37 | -15.57 | 32.05 | 35.59 |
| 5-year avg ROE %i | -61.16 | -61.62 | -57.20 | -47.83 | -43.45 | -34.35 | -18.59 | -2.12 |
| EBIT margin %i | -110.56 | -72.71 | -64.87 | -35.20 | -43.23 | -10.10 | 8.80 | 9.78 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 16.41 | 9.81 |
| Current ratioi | 8.83 | 10.16 | 6.77 | 6.43 | 4.04 | 2.42 | 2.38 | 3.83 |
| Quick ratioi | 8.42 | 9.83 | 6.44 | 6.10 | 3.82 | 2.13 | 2.18 | 3.49 |
| Debt / assetsi | 0.00 | 1.25 | 6.33 | 9.20 | 10.55 | 7.64 | 4.38 | 3.34 |
| LT debt / equityi | -- | 0.91 | 7.09 | 10.38 | 13.16 | 11.07 | 5.74 | 3.30 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 1,442.34 | 169.46 | 52.36 | 29.33 | 15.11 | 18.03 | 25.54 | 27.48 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 37.24 | 33.18 | 34.95 | 39.89 | 37.32 | 35.74 |
| ROA %i | 23.03 | 20.77 | 22.64 | 28.42 | 27.44 | 25.64 |
| ROIC %i | 30.46 | 27.30 | 29.05 | 35.59 | 33.63 | 31.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.87 | 8.86 | 9.02 | 9.78 | 7.39 | 7.59 |
| FCF / sales %i | 4.98 | 8.66 | 9.45 | 9.81 | 19.40 | 12.79 |
| Current ratioi | 2.88 | 2.91 | 3.02 | 3.83 | 3.59 | 3.39 |
| Quick ratioi | 2.63 | 2.67 | 2.77 | 3.49 | 3.27 | 3.11 |
| Debt / assetsi | 4.95 | 4.59 | 4.12 | 3.34 | 3.16 | 4.24 |
| LT debt / equityi | 5.83 | 5.42 | 4.69 | 3.30 | 3.13 | 4.56 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- NUPLAZID is the largest reported line at 59.47% of revenue, across 2 reported segments.
- DAYBUE follows at 40.53%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
NUPLAZID59.47%
DAYBUE40.53%
Quote time 2026-10-08 07:15:07 · For reference only, not investment advice and not tailored to your situation.